Chen, Wen <br/><br/>
Daclatasvir combined with asunaprevir is a cost-effective and cost-saving treatment for hepatitis C infection in China.  [electronic resource] 

 -  Journal of comparative effectiveness research  08 2018 
 - 785-795 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2042-6313 
<br/><br/><label>Standard No.: </label>10.2217/cer-2018-0005  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antiviral Agents--administration & dosage<br/>Carbamates<br/>China<br/>Cost-Benefit Analysis<br/>Drug Therapy, Combination<br/>Genotype<br/>Health Expenditures<br/>Health Resources--economics<br/>Hepatitis C, Chronic--drug therapy<br/>Humans<br/>Imidazoles--administration & dosage<br/>Isoquinolines--administration & dosage<br/>Life Expectancy<br/>Male<br/>Markov Chains<br/>Models, Econometric<br/>Pyrrolidines<br/>Quality-Adjusted Life Years<br/>Sulfonamides--administration & dosage<br/>Valine--analogs & derivatives